| Administration route |
intravenous infusion |
| Dosage |
0.5 E6 cells/kg, 1 E6 cells/kg |
| Donor type |
Autologous |
| Pts |
12 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
All patients generally reported improvement in disabilities and quality-of-life outcomes; 11 patients’ AQP-4 antibodies in serum showed a downward trend by the cutoff date. |
| Adverse reactions |
The most common events of grade 3 or higher were hematologic toxic effects. 58% developed infections, but no grade 4 infections occurred. Cytokine release syndrome was reported in all patients with only events of grade 1 or 2 observed. |
|